Publications

Journal Article
Research Support, Non-U.S. Gov't
Ppublish 45 citations
Electronic publication date
September 19, 2012

View on Pubmed.gov 22150233 | View on doi.org 10.1089/neu.201...

The systemic inflammatory response after spinal cord injury in the rat is decreased by α4β1 integrin blockade.

Search for publications in this journal J Neurotrauma - 29(8):1626-37

Abstract

Abstract The systemic inflammatory response syndrome (SIRS) follows spinal cord injury (SCI) and causes damage to the lungs, kidney, and liver due to an influx of inflammatory cells from the circulation. After SCI in rats, the SIRS develops within 12 h and is sustained for at least 3 days. We have previously shown that blockade of CD11d/CD18 integrin reduces inflammation-driven secondary damage to the spinal cord. This treatment reduces the SIRS after SCI. In another study we found that blockade of α4β1 integrin limited secondary cord damage more effectively than blockade of CD11d/CD18. Therefore we considered it important to assess the effects of anti-α4β1 treatment on the SIRS in the lung, kidney, and liver after SCI. An anti-α4 antibody was given IV at 2 h after SCI at the fourth thoracic segment and the effects on the organs were evaluated at 24 h post-injury. The migration of neutrophils into the lungs and liver was markedly reduced and all three organs contained fewer macrophages. In the lungs and liver, the activation of the oxidative enzymes myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and gp91(phox), the production of free radicals, lipid peroxidation, and cell death were substantially and similarly reduced. Treatment effects were less robust in the kidney. Overall, the efficacy of the anti-α4β1 treatment did not differ greatly from that of the anti-CD11d antibody, although details of the results differed. The SIRS after SCI impedes recovery, and attenuation of the SIRS with an anti-integrin treatment is an important, clinically-relevant finding.

References

Am J Pathol. 2005 May;166(5):1487-97

J Neurotrauma. 1994 Oct;11(5):447-72

Am Surg. 2001 Feb;67(2):122-6

J Pharmacol Exp Ther. 2003 Jun;305(3):1150-62

Cited by 45 citations (total)

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Imatinib enhances functional outcome after spinal cord injury.

Electronic publication date December 13, 2012

Search for publications in this journal PLoS One

Mathew B Abrams [...] Ulf Eriksson et al.

We investigated whether imatinib (Gleevec®, Novartis), a tyrosine kinase inhibitor, could improve functional outcome in experimental spinal cord injury. Rats...

Journal Article

The Transcriptional Response of Neurotrophins and Their Tyrosine Kinase Receptors in Lumbar Sensorimotor Circuits to Spinal Cord Contusion is Affected by Injury Severity and Survival Time.

Electronic publication date January 15, 2013

Search for publications in this journal Front Physiol

M Tyler Hougland [...] Jeffrey C Petruska et al.

Traumatic spinal cord injury (SCI) results in changes to the anatomical, neurochemical, and physiological properties of cells in the central...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances